title: Exercise attenuates levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned mice.
abstract: L-DOPA alleviates the motor symptoms of Parkinson's disease, but its long-term use is associated with undesirable dyskinesia. We now tested whether exercise can attenuate this L-DOPA-induced dyskinesia (LID). We tested the effects of exercise on LID in 6-hydroxydopamine hydrochloride-hemiparkinsonian mice. Animals were treated with L-DOPA/benserazide (25/12.5 mg/kg, i.p.) without and with possibility to exercise (running wheel) during 2 weeks. Exercise drastically prevented the development of LID, and its associated aberrant striatal signaling, namely the hyperphosphorylation of dopamine and cAMP-regulated phosphoprotein 32 kDa protein and c-Fos expression. Our results indicate that exercise can partially prevent the development of LID through the normalization of striatopallidal dopaminergic signaling.
authors.affiliation: Departamento de Farmacologia, Universidade Federal de Santa Catarina, 88040-900 Florianópolis, SC, Brazil. aderbalaguiar@gmail.com
authors.forename: A S
authors.initials: AS
authors.lastname: Aguiar
authors.forename: E L G
authors.initials: EL
authors.lastname: Moreira
authors.forename: A A
authors.initials: AA
authors.lastname: Hoeller
authors.forename: P A
authors.initials: PA
authors.lastname: Oliveira
authors.forename: F M
authors.initials: FM
authors.lastname: Córdova
authors.forename: V
authors.initials: V
authors.lastname: Glaser
authors.forename: R
authors.initials: R
authors.lastname: Walz
authors.forename: R A
authors.initials: RA
authors.lastname: Cunha
authors.forename: R B
authors.initials: RB
authors.lastname: Leal
authors.forename: A
authors.initials: A
authors.lastname: Latini
authors.forename: R D S
authors.initials: RD
authors.lastname: Prediger
mesh_terms: D000818:Animals; D000978:Antiparkinson Agents / Q000009:adverse effects*; D002851:Chromatography, High Pressure Liquid; D003342:Corpus Striatum / Q000378:metabolism / Q000503:physiopathology; D004409:Dyskinesia, Drug-Induced / Q000517:prevention & control*; D007150:Immunohistochemistry; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D016627:Oxidopamine / Q000633:toxicity; D020734:Parkinsonian Disorders / Q000188:drug therapy / Q000503:physiopathology*; D010805:Physical Conditioning, Animal
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa; D016627:Oxidopamine